Our Insights Oncology Anthony Iannacci 11/3/26 Oncology Anthony Iannacci 11/3/26 Pfizer’s Xtandi + Talzenna Combo Approved in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Scoring a Much Broader Label Than J&J’s Akeega Read More Oncology Anthony Iannacci 10/6/26 Oncology Anthony Iannacci 10/6/26 Zegfrovy Has Proven Itself to Be a Viable Alternative to Rybrevant + Chemotherapy in 1L EGFR EXON 20 Insertion-Mutated NSCLC Read More Want to get in touch? Click here
Oncology Anthony Iannacci 11/3/26 Oncology Anthony Iannacci 11/3/26 Pfizer’s Xtandi + Talzenna Combo Approved in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Scoring a Much Broader Label Than J&J’s Akeega Read More
Oncology Anthony Iannacci 10/6/26 Oncology Anthony Iannacci 10/6/26 Zegfrovy Has Proven Itself to Be a Viable Alternative to Rybrevant + Chemotherapy in 1L EGFR EXON 20 Insertion-Mutated NSCLC Read More